Danielle Brill

Stock Analyst at Truist Securities

(3.79)
# 728
Out of 5,044 analysts
88
Total ratings
43.42%
Success rate
12.06%
Average return

Stocks Rated by Danielle Brill

Alnylam Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $459$535
Current: $475.91
Upside: +12.42%
Immunovant
Oct 14, 2025
Initiates: Hold
Price Target: $16
Current: $21.98
Upside: -27.21%
Upstream Bio
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $24.84
Upside: +89.21%
Dianthus Therapeutics
Oct 14, 2025
Initiates: Buy
Price Target: $56
Current: $33.65
Upside: +66.42%
Palvella Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $56$80
Current: $73.50
Upside: +8.84%
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $422.39
Upside: -
Disc Medicine
Jul 21, 2025
Initiates: Buy
Price Target: $86
Current: $87.61
Upside: -1.84%
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $29.64
Upside: +61.94%
Tectonic Therapeutic
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $17.88
Upside: +257.94%
Neurocrine Biosciences
Jul 21, 2025
Initiates: Buy
Price Target: $163
Current: $147.38
Upside: +10.60%
Initiates: Buy
Price Target: $66
Current: $64.50
Upside: +2.33%
Initiates: Buy
Price Target: $30
Current: $25.02
Upside: +19.90%
Initiates: Buy
Price Target: $24
Current: $19.17
Upside: +25.20%
Upgrades: Strong Buy
Price Target: $20$52
Current: $70.00
Upside: -25.71%
Reinstates: Market Perform
Price Target: n/a
Current: $16.92
Upside: -
Reinstates: Outperform
Price Target: $79
Current: $53.49
Upside: +47.69%
Reinstates: Outperform
Price Target: $18
Current: $13.16
Upside: +36.78%
Reinstates: Outperform
Price Target: $150
Current: $24.22
Upside: +519.32%
Reinstates: Market Perform
Price Target: n/a
Current: $149.13
Upside: -
Reinstates: Strong Buy
Price Target: $605
Current: $836.39
Upside: -27.67%
Reinstates: Market Perform
Price Target: n/a
Current: $22.62
Upside: -
Reinstates: Outperform
Price Target: $50
Current: $42.53
Upside: +17.56%
Reinstates: Outperform
Price Target: $51
Current: $43.43
Upside: +17.43%
Maintains: Outperform
Price Target: $180$100
Current: $7.66
Upside: +1,205.48%
Downgrades: Underperform
Price Target: n/a
Current: $67.49
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $10.83
Upside: -